Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) stocks have downed by 58.5% and according to close sources this is a heaver blow on it trading due to the fact that recently, the company failed to show that the cannabidiol gel could work as far as the intended purposes were concerned. According to Paul Matteis, who is the Leerink Partners analyst, the fail trial was basically a clinical trial for Zynerba Pharmaceuticals Incorporation cannabidiol gel. The test was aimed at determining whether the gel could manage or even cure epilepsy in adults. This is the reason why the company’s stocks plunged down by 58.5%. This was a heavy blow as far as the stock trade was concerned.
GW Pharma Benefits from the Stock Downfall by Zynerba Pharmaceuticals
According to both internal and external business analysts, the rival GW Pharma which is based in the U.K has experienced an improvement in terms of stock value (+0.13%).
... read more at: https://www.wallstreetpr.com/zynerba-pharmaceuticals-inc-nasdaqzyne-failed-cannabidiol-trial-saw-gw-pharma-head-to-the-right-direction-after-becoming-the-best-alternative-cannabidiol-developing-company-40150